{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:43:02Z","timestamp":1777632182081,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04895-9","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:49:50Z","timestamp":1777434590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of venetoclax in a patient after whipple pancreaticoduodenectomy"],"prefix":"10.1007","volume":"96","author":[{"given":"Tien V.","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julianne L.","family":"Holleran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christinea","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Burrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashkan","family":"Emadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"4895_CR1","unstructured":"D\u2019Cruz JR, Misra S, Menon G, Shamsudeen S (2025) Pancreaticoduodenectomy (Whipple Procedure). In: Anonymous StatPearlsStatPearls Publishing; https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560747\/"},{"issue":"6","key":"4895_CR2","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1159\/000264638","volume":"9","author":"TCK Tran","year":"2009","unstructured":"Tran TCK, van Lanschot JJB, Bruno MJ, van Eijck CHJ (2009) Functional changes after pancreatoduodenectomy: diagnosis and treatment. Pancreatology 9(6):729\u2013737. https:\/\/doi.org\/10.1159\/000264638","journal-title":"Pancreatology"},{"issue":"3","key":"4895_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/MPA.0000000000000473","volume":"45","author":"DSJ Tseng","year":"2016","unstructured":"Tseng DSJ, Molenaar IQ, Besselink MG, van Eijck CH, Borel Rinkes IH, van Santvoort (2016) H,C. Pancreatic exocrine insufficiency in patients with pancreatic or periampullary cancer: A systematic review. Pancreas 45(3):325\u2013330. https:\/\/doi.org\/10.1097\/MPA.0000000000000473","journal-title":"Pancreas"},{"issue":"19","key":"4895_CR4","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.3748\/wjg.v21.i19.5794","volume":"21","author":"CM Kang","year":"2015","unstructured":"Kang CM, Lee JH (2015) Pathophysiology after pancreaticoduodenectomy. World J Gastroenterol 21(19):5794\u20135804. https:\/\/doi.org\/10.3748\/wjg.v21.i19.5794","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4895_CR5","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1245\/s10434-025-17087-1","volume":"32","author":"AV Maker","year":"2025","unstructured":"Maker AV (2025) Delayed Gastric Emptying After Whipple: Pyloric Manipulation Will Not Solve It, but the Body Compensates. Ann Surg Oncol 32(6):3861\u20133862. https:\/\/doi.org\/10.1245\/s10434-025-17087-1","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4895_CR6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11605-015-2795-2","volume":"19","author":"A El Nakeeb","year":"2015","unstructured":"El Nakeeb A, Askr W, Mahdy Y et al (2015) Delayed gastric emptying after pancreaticoduodenectomy. Risk factors, predictors of severity and outcome. A single center experience of 588 cases. J Gastrointest Surg 19(6):1093\u20131100. https:\/\/doi.org\/10.1007\/s11605-015-2795-2","journal-title":"J Gastrointest Surg"},{"key":"4895_CR7","doi-asserted-by":"publisher","first-page":"212574","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Juarez-Salcedo","year":"2019","unstructured":"Juarez-Salcedo LM, Desai V, Dalia S (2019) Venetoclax: evidence to date and clinical potential. Drugs Context 8:212574. https:\/\/doi.org\/10.7573\/dic.212574","journal-title":"Drugs Context"},{"issue":"5","key":"4895_CR8","doi-asserted-by":"publisher","first-page":"e13807","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem AH, Menon RM (2024) Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci 17(5):e13807. https:\/\/doi.org\/10.1111\/cts.13807","journal-title":"Clin Transl Sci"},{"issue":"12","key":"4895_CR9","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3390\/pharmaceutics12121175","volume":"12","author":"M Markovic","year":"2020","unstructured":"Markovic M, Zur M, Ragatsky I, Cvijic S, Dahan A (2020) BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics 12(12):1175. https:\/\/doi.org\/10.3390\/pharmaceutics12121175","journal-title":"Pharmaceutics"},{"key":"4895_CR10","unstructured":"U.S. Department of Health and Human Services Food and Drug, Administration, Center For Drug Evaluation And Research (2015). Clinical Pharmacology And Biopharmaceutics Review(S). U S Department Health Hum Serv Food Drug Adm https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208573Orig1s000ClinPharmR.pdf"},{"issue":"5","key":"4895_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40262-016-0453-9","volume":"56","author":"KJ Freise","year":"2017","unstructured":"Freise KJ, Jones AK, Eckert D et al (2017) Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Clin Pharmacokinet 56(5):515\u2013523. https:\/\/doi.org\/10.1007\/s40262-016-0453-9","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4895_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R et al (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naive acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40(2):269\u2013279. https:\/\/doi.org\/10.1002\/hon.2964","journal-title":"Hematol Oncol"},{"issue":"4","key":"4895_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/hon.2646","volume":"37","author":"S Agarwal","year":"2019","unstructured":"Agarwal S, Gopalakrishnan S, Mensing S et al (2019) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis. Hematol Oncol 37(4):464\u2013473. https:\/\/doi.org\/10.1002\/hon.2646","journal-title":"Hematol Oncol"},{"issue":"15","key":"4895_CR14","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","volume":"29","author":"D Levitz","year":"2023","unstructured":"Levitz D, Saunthararajah Y, Fedorov K et al (2023) A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine\/Venetoclax in MDS and AML. Clin Cancer Res 29(15):2774\u20132780. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0842","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4895_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/jcph.1633","volume":"62","author":"M Guidi","year":"2022","unstructured":"Guidi M, Csajka C, Buclin T (2022) Parametric approaches in population pharmacokinetics. J Clin Pharmacol 62(2):125\u2013141. https:\/\/doi.org\/10.1002\/jcph.1633","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4895_CR16","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38. https:\/\/doi.org\/10.1038\/psp.2013.14","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"4895_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood.2024024837","volume":"145","author":"Y Liu","year":"2025","unstructured":"Liu Y, Bollino DR, Bah OM et al (2025) A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia. Blood 145(5):486\u2013496. https:\/\/doi.org\/10.1182\/blood.2024024837","journal-title":"Blood"},{"issue":"8","key":"4895_CR18","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jcph.2248","volume":"63","author":"JQX Gong","year":"2023","unstructured":"Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023) Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials. J Clin Pharmacol 63(8):950\u2013960. https:\/\/doi.org\/10.1002\/jcph.2248","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"4895_CR19","first-page":"1","volume":"10","author":"B Bhatnagar","year":"2024","unstructured":"Bhatnagar B, Jordan C, Randall C et al (2024) Synchronous Cancers: Acute Myeloid Leukemia and Pancreatic Ductal Adenocarcinoma with Germline Heterozygous DDX41 and MUTYH Mutations in a Patient from Appalachia, United States. Oncol Cancer Case Rep 10(3):1. https:\/\/www.iomcworld.org\/open-access\/synchronous-cancers-acute-myeloid-leukemia-and-pancreatic-ductal-adenocarcinoma-with-germline-heterozygous-ddx41-and-mutyh-mutatio-110404.html#ai","journal-title":"Oncol Cancer Case Rep"},{"issue":"3","key":"4895_CR20","first-page":"90","volume":"1","author":"H Boxenbaum","year":"1998","unstructured":"Boxenbaum H (1998) Pharmacokinetics tricks and traps: flip-flop models. J Pharm Pharm Sci 1(3):90\u201391","journal-title":"J Pharm Pharm Sci"},{"key":"4895_CR21","doi-asserted-by":"publisher","unstructured":"Nandhra GK, Chaichanavichkij P, Birch M, Scott SM (2023) Gastrointestinal transit times in health as determined using ingestible capsule systems: A systematic review. J Clin Med 12(16). https:\/\/doi.org\/10.3390\/jcm12165272","DOI":"10.3390\/jcm12165272"},{"issue":"4","key":"4895_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SLH, Humerickhouse RA, Wong SL (2017) Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma. J Clin Pharmacol 57(4):484\u2013492. https:\/\/doi.org\/10.1002\/jcph.821","journal-title":"J Clin Pharmacol"},{"issue":"205","key":"4895_CR23","doi-asserted-by":"publisher","first-page":"205ra135","DOI":"10.1126\/scitranslmed.3006684","volume":"5","author":"RP Bakshi","year":"2013","unstructured":"Bakshi RP, Nenortas E, Tripathi AK, Sullivan DJ, Shapiro TA (2013) Model system to define pharmacokinetic requirements for antimalarial drug efficacy. Sci Transl Med 5(205):205ra135. https:\/\/doi.org\/10.1126\/scitranslmed.3006684","journal-title":"Sci Transl Med"},{"issue":"8","key":"4895_CR24","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/jac\/dkz160","volume":"74","author":"KJ Meyer","year":"2019","unstructured":"Meyer KJ, Meyers DJ, Shapiro TA (2019) Optimal kinetic exposures for classic and candidate antitrypanosomals. J Antimicrob Chemother 74(8):2303\u20132310. https:\/\/doi.org\/10.1093\/jac\/dkz160","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4895_CR25","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.jamcollsurg.2014.12.031","volume":"220","author":"JL Cameron","year":"2015","unstructured":"Cameron JL, He J (2015) Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg 220(4):530\u2013536. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2014.12.031","journal-title":"J Am Coll Surg"},{"issue":"8","key":"4895_CR26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/archsurg.1992.01420080079012","volume":"127","author":"BW Miedema","year":"1992","unstructured":"Miedema BW, Sarr MG, van Heerden JA, Nagorney DM, McIlrath DC, Ilstrup D (1992) Complications following pancreaticoduodenectomy. Current management. Arch Surg 127(8):945\u2013949 discussion 949. https:\/\/doi.org\/10.1001\/archsurg.1992.01420080079012","journal-title":"Arch Surg"},{"issue":"4","key":"4895_CR27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jamcollsurg.2007.01.018","volume":"204","author":"E Lermite","year":"2007","unstructured":"Lermite E, Pessaux P, Brehant O et al (2007) Risk factors of pancreatic fistula and delayed gastric emptying after pancreaticoduodenectomy with pancreaticogastrostomy. J Am Coll Surg 204(4):588\u2013596. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2007.01.018","journal-title":"J Am Coll Surg"},{"issue":"9","key":"4895_CR28","doi-asserted-by":"publisher","first-page":"e69406","DOI":"10.7759\/cureus.69406","volume":"16","author":"C Martinez-Cabrera","year":"2024","unstructured":"Martinez-Cabrera C, Martinez-Esteban A, Barron-Cervantes NM, Bandin-Musa A, Chan C (2024) Delayed Gastric Emptying and Other Adverse Outcomes in Patients Undergoing Classic Whipple Versus Pylorus-Sparing Pancreatoduodenectomy. Cureus 16(9):e69406. https:\/\/doi.org\/10.7759\/cureus.69406","journal-title":"Cureus"},{"issue":"11","key":"4895_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","volume":"56","author":"AH Salem","year":"2016","unstructured":"Salem AH, Agarwal SK, Dunbar M et al (2016) Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor. J Clin Pharmacol 56(11):1355\u20131361. https:\/\/doi.org\/10.1002\/jcph.741","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"4895_CR30","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1007\/s12325-022-02170-w","volume":"39","author":"D Samineni","year":"2022","unstructured":"Samineni D, Gibiansky L, Wang B et al (2022) Pharmacokinetics and Exposure-Response Analysis of Venetoclax\u2009+\u2009Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial. Adv Ther 39(8):3635\u20133653. https:\/\/doi.org\/10.1007\/s12325-022-02170-w","journal-title":"Adv Ther"},{"issue":"1","key":"4895_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12325-021-01919-z","volume":"39","author":"D Samineni","year":"2022","unstructured":"Samineni D, Huang W, Gibiansky L et al (2022) Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed\/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma. Adv Ther 39(1):598\u2013618. https:\/\/doi.org\/10.1007\/s12325-021-01919-z","journal-title":"Adv Ther"},{"issue":"12","key":"4895_CR32","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40262-019-00788-8","volume":"58","author":"R Deng","year":"2019","unstructured":"Deng R, Gibiansky L, Lu T et al (2019) Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clin Pharmacokinet 58(12):1621\u20131634. https:\/\/doi.org\/10.1007\/s40262-019-00788-8","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"4895_CR33","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s40262-017-0625-2","volume":"57","author":"M Minocha","year":"2018","unstructured":"Minocha M, Zeng J, Medema JK, Othman AA (2018) Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus. Clin Pharmacokinet 57(9):1185\u20131198. https:\/\/doi.org\/10.1007\/s40262-017-0625-2","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4895_CR34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","volume":"18","author":"AK Jones","year":"2016","unstructured":"Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH (2016) Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin\u2019s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. AAPS J 18(5):1192\u20131202. https:\/\/doi.org\/10.1208\/s12248-016-9927-9","journal-title":"AAPS J"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04895-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04895-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:49:59Z","timestamp":1777434599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04895-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4895"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04895-9","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing financial interests. No specific funding was used to prepare this manuscript. Written informed consent was obtained from the patient for publication of this case. The report was prepared in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"42"}}